Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations
- 1 December 1990
- journal article
- research article
- Published by Springer Science and Business Media LLC in European Journal of Clinical Pharmacology
- Vol. 39 (6), 533-537
- https://doi.org/10.1007/bf00316090
Abstract
No abstract availableKeywords
This publication has 34 references indexed in Scilit:
- DISASSOCIATION BETWEEN DEBRISOQUINE HYDROXYLATION PHENOTYPE AND GENOTYPE AMONG CHINESEThe Lancet, 1989
- Polymorphic drug oxidation: pharmacokinetic basis and comparison of experimental indices.British Journal of Clinical Pharmacology, 1986
- The influence of enzyme induction on polymorphic sparteine oxidation.British Journal of Clinical Pharmacology, 1986
- Metoprolol metabolism and debrisoquine oxidation polymorphism‐ population and family studies.British Journal of Clinical Pharmacology, 1985
- Balanced Pharmacokinetics and Metabolism of BisoprololJournal of Cardiovascular Pharmacology, 1985
- Sparteine Oxidation Polymorphism in DenmarkActa Pharmacologica et Toxicologica, 1985
- A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population.Journal of Medical Genetics, 1980
- POLYMORPHIC HYDROXYLATION OF DEBRISOQUINE IN MANThe Lancet, 1977
- ENZYME DIVERSITY IN HUMAN POPULATIONSAnnals of the New York Academy of Sciences, 1968
- Genetic Control of Isoniazid Metabolism in ManBMJ, 1960